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The cerebral vasoregulation incorporates various local and global regulatory 
mechanisms, involving participation of neuronal and vascular elements. 
Cerebrovascular control pathways have been studied extensively for decades, but 
several important questions, like the exact mechanism of flow-metabolism coupling or 
hypercapnia- and hypoxia-induced vasodilation, are still not clarified completely. In our 
works we hypothesized that investigation of recently discovered vasoactive mediators 
may shed light on obscure details of the regulation of cerebral circulation. 
Carbon monoxide (CO), which was previously considered only as a highly toxic and 
life-threatening pollutant, has been recognized recently as an important messenger in 
numerous physiological and pathophysiological processes. Endogenous CO is produced 
primarily by two heme oxygenase (HO) isoenzymes, HO-1 and HO-2. Analogous to 
nitric oxide synthase (NOS), the HO enzymes are widely distributed in the 
cardiovascular as well as in the central and peripheral nervous systems. CO and nitric 
oxide (NO) also display notable similarities with regards to their physiological roles, as 
both molecules appear to be neurotransmitters in the brain and peripheral autonomic 
nervous system. Furthermore, both CO and NO are capable of inducing vasodilation as 
well as inhibiting the proliferation of vascular smooth muscle cells. Although the 
expression of HO isoenzymes in the brain and cerebral vessels is well documented, the 
role of endogenous CO in the regulation of the cerebral circulation is far less understood 
than that of NO. In our studies we investigated the influence of the HO pathway on the 
cerebrocortical circulation in adult animals. 
Endocannabinoids are endogenous bioactive lipid mediators exerting many of their 
effects in mammals through their specific G protein-coupled receptors. The main 
endocannabinoids are anandamide and 2-arachidonoyl glycerol (2-AG), the former 
favoring cannabinoid receptor 1 (CB1) and the latter, cannabinoid receptor 2 (CB2). 
These receptors are also involved in mediating the effect of several constituent 
compounds of the plant Cannabis sativa (marijuana). Endocannabinoids have been 
implicated in many physiological functions and also in pathophysiological processes, 
such as diseases and aging of the cardiovascular system, ischemia-reperfusion injury, 
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hypertension, diabetes and obesity. The role of the endocannabinoid system in the 
regulation of cerebral blood flow is, however, still largely unknown. It was recognized 
very early that Δ9-Tetrahydrocannabinol is able to increase brain perfusion in dogs, and 
this observation has recently been verified with positron emission tomography in 
humans. Furthermore, administration of anandamide dilated cerebral arterioles of 
rabbits and isolated cerebral arteries of cats, but caused a decrease in cerebral blood 
flow in rats. In other in vivo observations in rats, however, both anandamide and the 
CB1-receptor agonist HU-210 elicited marked cerebral vasodilation, which was 
inhibited by a CB1-antagonist. To address these contradictory findings and to clarify the 
role of endocannabinoids and CB1-receptors in cerebral circulation, we carried out 
experiments in rats with the administration of a CB1 receptor antagonist / reverse 
agonist (AM-251) under resting physiological conditions and we also examined the role 
of CB1-receptors in hypoxia and hypercapnia. 
2.  SPECIFIC AIMS 
The central nervous system is an independent functional HO unit which contains the 
substrate, enzymes and co-factors for the synthesis of CO. Furthermore, several cell 
types of the brain are able to produce endocannabinoids and express their receptors. 
Since both endogenous CO and endocannabinoids were previously shown to have 
vascular effects we hypothesized that they may be involved in the regulation of the 
cerebral circulation. Specifically, we aimed to describe the roles of both the HO 
pathway and the endocannabinoid system on cerebrocortical blood flow (CBF) under 
resting conditions as well as during combined hypoxia and hypercapnia (H/H).  
1. First, we aimed to examine the effect of the HO inhibitor ZnDPBG on the CBF 
under resting conditions in anesthetized adult male rats, by measuring the CBF in 
the parietal cortex. We also addressed the potential interaction between the HO and 
NOS pathways in the regulation of the cerebrocortical blood flow under resting 
conditions.  
2. Next, we observed the effect of the HO inhibitor ZnDPBG on the cerebrovascular 
effects of stepwise hypoxia/hypercapnia (H/H) by measuring the CBF in the parietal 
cortex of anesthetized adult male rats.  
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3. Following this, we aimed to study the effects of the cannabinoid CB1 receptor 
antagonist / reverse agonist AM251 on the cerebrocortical blood flow under resting 
conditions using similar methods.  
4. Finally, we examined the effect of CB1-blockade by AM251 on the CBF rise to 
stepwise H/H.  
3.  Materials and Methods 
3.1 Experimental animals, anaesthesia and surgical procedures  
The experiments were carried out on adult male Wistar rats (300-400 g) anesthetized 
with urethane (1.3 g/kg ip.), and spontaneously breathing via the cannulated trachea. 
Depth of anesthesia was regularly controlled during the experiments by checking the 
corneal nociception reflexes, and when necessary, additional urethane was administered 
intravenously. Catheters were inserted into the right femoral artery for measuring 
systemic arterial blood pressure, into the left femoral artery for blood sampling, and into 
the left femoral vein for drug administration.  
3.2 Routinely recorded physiological variables 
Systemic arterial blood pressure was continuously recorded on a Grass polygraph 
(Model 7E, Natus Neurology Incorporated, Warwick, RI, USA). Arterial blood gas 
values (aPCO2, aPO2 and O2-saturation) and acid-base parameters (apH and standard 
base excess) were measured by an ABL-300 Blood Gas Analyzer (Radiometer, 
Brønshøj, Denmark) in femoral arterial samples. Body temperature was kept constant 
between 36-38 ºC with a controlled heating pad. 
3.3 Measurement of the cerebral blood flow 
Cerebrocortical blood flow (CBF), more precisely red blood cell flux, was measured in 
the parietal cortex by laser-Doppler (LD) flowmetry. The skull of the rat was fixed in a 
stereotaxic head holder, the parietal region was exposed and the bone was thinned over 
the parietal cortex on both sides with a microdrill, so that the lamina interna of the skull 
remained intact. LD flow (LDF) was measured with a two-channel LDF monitor (Moor 
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Instruments, Devon, UK) and recorded continuously. The laser light was in the infrared 
range (780 nm) and penetrated about 1 mm into the brain covering approximately 7 
mm
2
 of the parietal region, so that the data acquired represented the characteristics of 
the parietal cortex. The two LD flow data sets gained from the parietal region of both 
hemispheres of the animal were evaluated and treated as independent measurements. 
3.4 Experimental Protocols  
3.4.1 The influence of HO pathway on cerebrocortical blood flow 
3.4.1.1 First experimental protocol: the influence of HO pathway on CBF under 
normoxic/normocapnic conditions    
In the first experimental protocol, the effect of HO blockade on the CBF was studied 
under physiological normoxic/normocapnic conditions. Animals of the first 
experimental group (n=9) served as a vehicle-treated control and CBF was determined 
before and after an intraperitoneal injection of 3 mL saline. In the second experimental 
group (n=9), 45 µmol/kg zinc deuteroporphyrin 2,4-bis glycol (ZnDPBG, Frontier 
Scientific, Logan, UT, USA) was applied in 3 mL saline intraperitoneally for the 
inhibition of the HO pathway. CBF was determined before as well as 15, 30, and 45 
minutes after the administration of either saline or ZnDPBG. To verify the inhibitory 
effect of ZnDPBG on brain HO activity in vivo, matched series of animals were treated 
with either ZnDPBG or vehicle as described above. ZnDPBG induced a reduction of 
cerebral HO activity from 4.58 ± 0.87 to 2.47 ± 0.36 µmol / kg per hour (p = 0.025). 
In order to investigate the interaction of the NOS and HO systems, more precisely, the 
effect of suppression of NO production on CO-induced CBF-changes, the synthesis of 
NO was inhibited. Therefore, animals in the third and fourth experimental groups 
were pretreated intravenously with the NO-synthase inhibitor L-NAME (N
G
-nitro-L-
arginine methyl ester) in a dose of 50 mg/kg, 30 minutes prior to the administration of 
saline (n=5) or ZnDPBG (n=6), respectively. The CBF of the L-NAME pretreated rats 
was determined before as well as 15, 30, and 45 minutes after the administration of 
saline or ZnDPBG. 
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3.4.1.2 Second experimental protocol: the effect of HO blockade on the CBF rise to H/H 
In the second experimental protocol, the effect of HO blockade on the CBF increase to 
H/H was observed. Stepwise H/H was induced by administration of different gas 
mixtures (5%O2-20%CO2-75%N2 for producing moderate H/H and 20%CO2-80%N2 for 
producing severe H/H) with a constant flow rate of 3 L/min into a 5 mL chamber 
connected to the trachea. Since one side of the chamber was open, the pressure in the 
chamber was not different from the atmospheric pressure. CBF was recorded 
continuously. Peak CBF values were determined during the two steps of H/H, each with 
a duration of 10 minutes. After the first stepwise H/H round, the inhalation of the gas 
mixture was stopped, and following a thirty minute recovery period of normal air 
breathing, the animals were divided into two experimental groups, thus receiving 
intraperitoneally either 3 ml saline or 45 micromol/kg ZnDPBG dissolved in the same 
amount of saline. Thirty minutes following intraperitoneal drug treatment, the stepwise 
H/H was repeated in both experimental groups with continuous recording of the CBF, 
from which peak CBF values were determined again. 
3.4.2 Influence of endocannabinoids on cerebral circulation 
3.4.2.1 Third experimental protocol: the influence of CB1 receptor blockade on the 
CBF under normoxic/normocapnic conditions 
In the third experimental protocol, the influence of CB1-receptors on the CBF under 
resting conditions was investigated. After a 15 min baseline period, the control (first) 
experimental group received vehicle-treatment (1 ml of saline, ethanol and emulfor iv. 
in a volume ratio of 1:1:8 of ethanol-emulphor-saline). The treated (second) 
experimental group was administered intravenously 10 mg/kg of CB1 receptor 
antagonist / reverse agonist AM251. AM251 (1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-
4methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide) was obtained from Cayman 
Chemicals (Ann Arbor, MI, USA) and dissolved in 1 mL of vehicle containing 
ethanol/emulphor/saline (1:1:8; v:v:v). Blood samples were taken before as well as 15, 
30, and 45 minutes after the administration of AM251 or its vehicle. 
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3.4.2.2 Fourth experimental protocol: the effect of CB1 receptor blockade on the CBF 
rise to H/H 
With the fourth experimental protocol, the main goal of the investigation was to study 
the effect of the cannabinoid CB1 receptor antagonist AM251 on the cerebrocortical 
hyperemic response to controlled stepwise H/H. In this case, 3 steps of H/H were 
induced by inhalation of different gas mixtures with a constant flow rate of 3 L/min into 
a 5 ml chamber connected to the trachea as described above. Peak CBF values were 
determined during the three, 10-min long steps of H/H.   
In the first step, during mild H/H, animals inhaled a gas mixture of 10%O2-10%CO2-
80%N2, which produced arterial pO2 of 75-85 mmHg and pCO2 of 50-60 mmHg. In the 
second step, during moderate H/H, animals inhaled a gas mixture of 5%O2-20%CO2-
75%N2, which produced arterial pO2 of 55-65 mmHg and pCO2 of 80-90 mmHg. In the 
third step, during severe H/H, animals inhaled gas mixtures of 0%O2-20%CO2-80%N2, 
which produced arterial pO2 of 45-50 mmHg and pCO2 of 90-100 mmHg.  
After the severe H/H step, the inhalation of the gas mixture was stopped, and following 
a thirty minute recovery period of normal air breathing, the animals received various 
drug treatments, depending on the experimental groups they were in.  The animals were 
randomly divided into two experimental groups receiving either vehicle or AM251 (10 
mg/kg i.v.). After another thirty minutes period following drug treatment, the stepwise 
H/H was repeated in all experimental groups with continuous recording of the CBF, and 
determination of peak CBF values. 
3.5 Drugs and chemicals 
ZnDPBG was purchased from Frontier Scientific, Logan, UT, USA, and AM251 from 
Cayman Chemicals, Ann Arbor, MI, USA. All other chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). 
3.6 Statistical analysis 
Statistical analysis was performed using Student’s t-test for comparision of two values 
as well as ANOVA for repeated measurements or one way ANOVA followed by 
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Tukey’s post-hoc test for three or more values. A p value of less than 0.05 was 
considered to be statistically significant. 
4. RESULTS 
4.1 Effects of heme-oxygenase blockade under resting 
normoxic/normocapnic conditions 
Baseline arterial blood gas and acid-base parameters were within the physiological 
range and showed no significant changes after the administration of ZnDPBG or its 
vehicle (saline). Neither ZnDPBG nor its vehicle induced any significant changes in the 
mean arterial blood pressure (Figure 1). In contrast, administration of ZnDPBG but not 
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Figure 1.  Mean arterial blood pressure (MAP) before (0 min) as well as 15, 30, 45 min after 
intraperitoneal injection of saline (open triangles, n=9) or 45 μmol/kg zinc deuteroporphyrin 
2,4-bis glycol (ZnDPBG) (open circles, n=9) in control rats as well as in rats pretreated with 
N
G
-nitro-L-arginine methyl ester (L-NAME) (filled symbols, n=5 for saline after L-NAME and 
n=6 for ZnDPBG after L-NAME). Values are presented as mean ± SEM. At all four timepoints, 
there was a significant (***p<0.001) increase of MAP in L-NAME pre-treated animals, 
compared to rats with intact NO synthesis. 
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Figure 2. Cerebrocortical blood flow (CBF) before (0 min) as well as 15, 30, 45 min after 
intraperitoneal injection of saline (triangles) or 45 micromol/kg zinc deuteroporphyrin 2,4-bis 
glycol (ZnDPBG; circles) in control (open symbols) or in N
G
-nitro-L-arginince methyl ester (L-
NAME) pretreated (filled symbols) rats. *p=0.016, ***p< 0.001 vs. ‘0min.’ with repeated 
measures analysis of variance and Tukey’s post hoc test, n= 10-16. AU, arbitrary unit. 
 
In order to evaluate the role of NO in mediating the enhancement of the CBF after HO 
blockade, the experiments have been repeated in animals subjected to inhibition of the 
NO synthesis. Administration of L-NAME increased mean arterial blood pressure from 
102.2 ± 3.0 to 146.3 ± 4.1 mmHg (p< 0.001), decreased heart rate from 424 ± 12 to 373 
± 12 beats/min (p= 0.012) and reduced CBF from 359 ±18 to 258±13 AU (p<0.001) 

























animals, neither ZnDPBG nor its vehicle induced any significant changes in the mean 
arterial blood pressure (Figure 1) or arterial blood gas and acid-base parameters. Most 
importantly, L-NAME prevented completely the enhancement of the CBF after 
inhibition of the endogenous CO production by administration of ZnDPBG (Figure 2).  
4.2 Effects of heme-oxygenase blockade on the hypoxia and 
hypercapnia induced increase of cerebrocortical blood flow 
Before the initial H/H challenge, baseline cardiovascular, arterial blood gas and acid-
base parameters were within physiological ranges in later ZnDPBG treated or saline 
treated experimental groups. During moderate H/H, PaO2 was reduced to 60-65 mmHg, 
PaCO2 was increased to 80-85 mmHg (Figure 3) and pH decreased to 7.10-7.15 Despite 
no change in MAP (data not shown), CBF increased in both experimental groups by ~ 
45% (Figure 4A). During severe H/H, PaO2 was reduced to 45-50 mmHg, PaCO2 was 
increased to 95-100 mmHg (Figure 3) and pH decreased to 7.05-7.10; CBF increased in 
both experimental groups by ~65% (Figure 4B), whereas MAP remained unchanged.  
The second stepwise H/H challenge, after ZnDPBG or saline, induced similar changes 
in the blood-gas tensions and pH as the initial challenge had done (Figure 3), without 
affecting MAP. Most importantly, neither ZnDPBG nor saline treatment had any effect 
on CBF responses to moderate (Figure 4A) or severe (Figure 4B) H/H, when compared 
to the pretreatment values.  
   
Figure 3. Arterial blood-
gas tensions during mild 
and severe H/H before 
(open symbols) and after 
(filled symbols) intra-
peritoneal injection of 
saline (triangles, n=8) or 45 
μmol/kg zinc deutero-
porphyrin 2,4-bis glycol 












Figure 4. Changes of the 
cerebrocortical blood flow 
(CBF) during moderate (A) and 
severe (B) hypoxia/hypercapnia 
(H/H) before (open bars) and 
after (filled bars) intraperitoneal 
injection of saline (n=16) or 45 
μmol /kg zinc deuteroporphyrin 
2,4-bis glycol (ZnDPBG, n=16). 
 
 
4.3 Influence of endocannabinoids on the cerebrocortical blood flow 
under resting conditions  
The influence of constitutive CB1-receptor activity on the resting blood pressure and 
CBF was studied by i.v. administration of the selective CB1 antagonist / reverse agonist 
AM-251 in a dose of 10 mg/kg, which had been shown to be effective in blocking CB1 
receptors in previous studies. Vehicle-treated animals served as controls.  Neither AM-
251 nor its vehicle induced any significant changes in the mean aterial blood pressure 
MAP (Figure 5A), heart rate HR (Figure 5B) or CBF (Figure 5C) up to 45 minutes after 
their administration. Furthermore, arterial blood gas tensions and acid-base parameters 
remained unchanged during the observation period. These findings indicate that 
constitutive CB1 activity has no significant influence on the systemic and 





Mean aterial blood pressure (MAP, panel A), heart rate (HR, panel B) and cerebrocortical blood 
flow (CBF, panel C) are shown before (0 minute) as well as 15, 30, 45 minutes after intravenous 
administration of 10 mg/kg of the CB 1 receptor antagonist AM251 (open squares, n=7) or its 
vehicle (open circles, n=5) in urethane-anaesthetized  rats. Values are presented as mean ± 
SEM. No significant change of the measured variables was found at any given time points after 
the administration of vehicle or AM-251. AU, arbitrary unit. 
 
4.4 Effects of endocannabinoid receptor blockade on the 
cerebrocortical blood flow during hypoxia and hypercapnia 
To test the effects of endocannabinoid receptor blockade on the CBF elevation during 
hypoxia and hypercapnia, we produced stepwise H/H (as described in the Methods) 
before and after the administration of AM-251 or its vehicle, and determined the 
changes in CBF. Inhalation of three different gas mixtures containing decreased O2- and 
increased CO2-content (as compared to air) induced reproducible levels of hypoxia and 
hypercapnia before and after the intravenous administration of 10 mg/kg AM-251 
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(Figure 6B) or its vehicle (Figure 6A), without significant changes in the BP. The H/H-
induced enhancement of CBF was identical before and after the administration of the 
vehicle (Figure 7A). In contrast, AM-251 resulted in markedly increased CBF changes 
during mild and moderate H/H (by 28.1 ± 8.8% and 39.4 ± 10.0%, respectively) without 
significantly influencing the peak CBF during severe H/H (Figure 7B). 
 
Figure 6.  
Inhalation of three different gas mixtures containing decreased O2- and increased CO2-content 
(as compared to air) induced reproducible levels of hypoxia and hypercapnia before and after 




The hypoxia/hypercapnia (H/H) induced enhancement of the cerebrocortical blood flow (CBF) 
was identical before and after the administration of the vehicle of AM-251 (panel A). In 
contrast, AM-251 resulted in markedly increased CBF changes during mild and moderate H/H 
(by 28.1 ± 8.8% and 39.4 ± 10.0%, respectively) without significantly influencing the peak CBF 
during severe H/H (panel B). 
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5. CONCLUSIONS 
1. First, we examined the effect of the HO inhibitor ZnDPBG on the CBF under 
resting conditions in anesthetized adult male rats, by measuring the CBF in the parietal 
cortex. We also aimed to examine the interaction between the HO and NOS pathways in 
the regulation of the cerebrocortical blood flow under resting conditions. The results of 
our study indicate that endogenous CO influences tonically the resting cerebrocortical 
blood flow by interacting with the NO synthesis. Inhibition of the HO pathway leads to 
cerebrocortical hyperemia by increased neuronal and/or endothelial NO production. 
2. We observed the effect of the HO inhibitor ZnDPBG on the cerebrovascular 
effects of stepwise hypoxia/hypercapnia by measuring the CBF in the parietal cortex of 
anesthetized adult male rats under hypoxia/hypercapnia. We found that the HO – CO 
pathway does not appear to influence the CBF increase during hypoxia and hypercapnia 
in adult rats. 
3. Following this, we studied the effects of the cannabinoid CB1 receptor blockade 
by the reverse agonist / antagonist AM251 on the CBF under resting conditions using 
similar methods. Our study indicates that under resting physiological conditions CB1-
receptor mediated mechanisms have limited tonic influence on the systemic and 
cerebral circulation. 
4. Finally, we examined the effect of AM251 on the CBF rise to stepwise H/H. 
Most importantly, our data suggest that the endocannabinoid system and CB1-receptors 
play an important role in the regulation of the cerebral circulation during hypoxia and 






6. LIST OF PUBLICATIONS 
Articles 
  1. Leszl-Ishiguro M, Horváth B, Johnson RA, Johnson FK, Lenzsér G, Hermán P, 
Horváth EM, Benyó Z: Influence of the heme oxygenase pathway on 
cerebrocortical blood flow. NeuroReport, 2007; 18: 1193-1197 (IF: 2.163) 
  2. *Iring A, *Ruisanchez É, *Leszl-Ishiguro M, Horváth B, Benkő R, Lacza Z, Járai 
Z, Sándor P, Di Marzo V, Pacher P, Benyó Z: Role of endocannabinoids and 
cannabinoid-1 receptors in cerebrocortical blood flow regulation. PLoS One, 2013; 
8(1): e53390 (IF: 3.730) 
*These authors contributed equally to the publication. 
 
Abstracts 
1. Horváth B, Ishiguro M, Hrabák A, Káldi K, Lacza Z, Sándor P, Benyó Z: 
Interaction between the heme oxygenase and nitric oxide pathways in the 
regulation of the resting CBF. Journal of Cerebral Blood Flow and 
Metabolism, 2003; 23: S77 (XXIst International Symposium on Cerebral Blood 
Flow, Metabolism and Function, June-July 2003, Calgary, Canada) 
2. Ishiguro M, Lacza Z, Horváth EM, Járai Z, Sándor P, Benyó Z: The 
cannabinoid receptor antagonist AM-251 enhances the cerebrocortical 
hyperemic response to hypoxia/hypercapnia. The FASEB Journal, 2004; 18: 
A267 (Experimental Biology, April 2004, Washington D.C., USA) 
3. Horváth B, Ishiguro M, Lenzsér G, Hermán P, Hrabák A, Káldi K, Sándor P, 
Benyó Z: Interaction between the heme oxygenase (HO) and NO synthase 
pathways in the regulation of the resting CBF. The FASEB Journal, 2004; 18: 
A268 (Experimental Biology, April 2004, Washington D.C., USA) 
 15 
4. Horváth B, Ishiguro M, Hortobágyi L, Lenzsér G, Hermán P, Hrabák A, Káldi 
K, Sándor P, Benyó Z: Role of the heme oxygenase pathway in the regulation of 
the resting CBF. Acta Physiologica Hungarica, 2004; 91: 302-303 (68
th
 Annual 
Meeting of the Hungarian Physiological Society, June 2004, Debrecen, 
Hungary) 
5. Ishiguro M, Lacza Z, Horváth EM, Járai Z, Sándor P, Benyó Z: Role of 
cannabinoid 1 receptor in the modulation of the cerebrocortical hyperemic 
response to hypoxia/hypercapnia. Acta Physiologica Hungarica, 2004; 91: 
311-312 (68
th
 Annual Meeting of the Hungarian Physiological Society, June 
2004, Debrecen, Hungary) 
6. Ishiguro M, Lacza Z, Horváth EM, Járai Z, Sándor P, Benyó Z: Inhibition of 
the cannabinoid-1 receptor enhances the cerebrocortical hyperemic response to 
hypoxia/hypercapnia. Journal of Cerebral Blood Flow and Metabolism, 
2005; 25: S189 (XXIInd International Symposium on Cerebral Blood Flow, 
Metabolism, and Function, June 2005, Amsterdam, The Netherlands) 
7. Ruisanchez É, Benkő R, Leszl-Ishiguro M, Lacza Z, Járai Z, Sándor P, Benyó 
Z: Cerebrovascular effects of endocannabinoids. Diabetologia, 2009; 52: S258, 
2009 (45
th
 Annual Meeting of the European Association for the Study of 
Diabetes, September-October 2009, Vienna, Austria) 
8. Ruisanchez É, Leszl IM, Benkő R, Lacza Z, Járai Z, Sándor P and Benyó Z 
(2009). Role of endocannabinoids in the regulation of the cortical blood flow. 
Front. Syst. Neurosci. Conference Abstract: 12th Meeting of the Hungarian 







I would like to thank my tutors Dr. Zoltán Benyó and Dr. Péter Sándor for giving me 
the possibility to carry out the whole experimental research in their laboratory, to 
complete my PhD studies, and to develop mentally. I thank my colleagues at the 
Semmelweis University for their continous support. I thank my coherent family for their 
patience, support, love and kindness and for keeping me intact for all these years. 
 
